Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus

Virology

Volumn 442, Issue 2, 2013, Pages 114-121

  Lee, Andrew M ^a   Cruite, Justin ^a   Welch, Megan J ^a   Sullivan, Brian ^a   Oldstone, Michael B A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Dendritic cell; Immune response; Lassa Gp recombinant virus; Pathogenesis

Indexed keywords

FATTY ACID BINDING PROTEIN; RNA POLYMERASE; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; INOCULATION; LASSA FEVER; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY CELL; MOUSE; NEWBORN; NONHUMAN; PATHOGEN CLEARANCE; PATHOGENESIS; PRIORITY JOURNAL; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; LASSA FEVER; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; RECOMBINATION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRAL TROPISM;

LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MUS;

EID: 84879168155     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.04.010     Document Type: Article

References (40)

1. Baize S., Kaplon J., Faure C., Pannetier D., Georges-Courbot M.C., Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 2004, 172:2861-2869.
2. Baize S., Pannetier D., Faure C., Marianneau P., Marendat I., Georges-Courbot M.C., Deubel V. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect. 2006, 8:1194-1202.
3. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
4. Berger D.P., Homann D., Oldstone M.B. Defining parameters for successful immunocytotherapy of persistent viral infection. Virology 2000, 266:257-263.
5. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287:2391-2405.
6. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12:1301-1309.
7. Buchmeier M.J., de la Torre J.C., Peters C.J. Arenaviridae: the viruses and their replication. Fields Virology 2007, 1791-1828:p. Lippincott-Raven, Philadelphia. 4th ed.
8. Cao W., Henry M.D., Borrow P., Yamada H., Elder J.H., Ravkov E.V., Nichol S.T., Compans R.W., Campbell K.P., Oldstone M.B. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998, 282:2079-2081.
9. Emonet S.E., Urata S., de la Torre J.C. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology 2011, 411:416-425.
10. Emonet S.F., Garidou L., McGavern D.B., de la Torre J.C. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl. Acad. Sci. U.S.A 2009, 106:3473-3478.
11. Flatz L., Rieger T., Merkler D., Bergthaler A., Regen T., Schedensack M., Bestmann L., Verschoor A., Kreutzfeldt M., Bruck W., Hanisch U.K., Gunther S., Pinschewer D.D. T-cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 2010, 6:e1000836.
12. Freedman D.O., Woodall J. Emerging infectious diseases and risk to the traveler. Med. Clin. North Am. 1999, 83:865-883.
13. Geisbert T.W., Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 2004, 10:S110-121.
14. Holmes G.P., McCormick J.B., Trock S.C., Chase R.A., Lewis S.M., Mason C.A., Hall P.A., Brammer L.S., Perez-Oronoz G.I., McDonnell M.K., et al. Lassa fever in the United States. Investigation of a case and new guidelines for management. N. Engl. J. Med. 1990, 323:1120-1123.
15. Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin. Infect. Dis. 2001, 33:1707-1712.
16. Kunz S., Sevilla N., McGavern D.B., Campbell K.P., Oldstone M.B. Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J. Cell Biol. 2001, 155:301-310.
17. Lewicki H., Tishon A., Borrow P., Evans C.F., Gairin J.E., Hahn K.M., Jewell D.A., Wilson I.A., Oldstone M.B. CTL escape viral variants. I. Generation and molecular characterization. Virology 1995, 210:29-40.
18. Lewicki H.A., Von Herrath M.G., Evans C.F., Whitton J.L., Oldstone M.B. CTL escape viral variants II. Biologic activity in vivo. Virology 1995, 211:443-450.
19. Mahanty S., Hutchinson K., Agarwal S., McRae M., Rollin P.E., Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 2003, 170:2797-2801.
20. McCormick J.B., Fisher-Hoch S.P. Lassa fever. Curr. Top. Microbiol. Immunol. 2002, 262:75-109.
21. Oldstone M.B., Blount P., Southern P.J., Lampert P.W. Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature 1986, 321:239-243.
22. Oldstone M.B., Campbell K.P. Decoding arenavirus pathogenesis: essential roles for alpha-dystroglycan-virus interactions and the immune response. Virology 2011, 411:170-179.
23. Pannetier D., Reynard S., Russier M., Journeaux A., Tordo N., Deubel V., Baize S. Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J. Virol. 2011, 85:8293-8306.
24. Popkin D.L., Teijaro J.R., Lee A.M., Lewicki H., Emonet S., de la Torre J.C., Oldstone M. Expanded potential for recombinant trisegmented lymphocytic choriomeningitis viruses: protein production, antibody production, and in vivo assessment of biological function of genes of interest. J. Virol. 2011, 85:7928-7932.
25. Riviere Y., Southern P.J., Ahmed R., Oldstone M.B. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. V. Recognition is restricted to gene products encoded by the viral S RNA segment. J. Immunol. 1986, 136:304-307.
26. Rojek J.M., Sanchez A.B., Nguyen N.T., de la Torre J.C., Kunz S. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J. Virol. 2008, 82:7677-7687.
27. Schmitz H., Kohler B., Laue T., Drosten C., Veldkamp P.J., Gunther S., Emmerich P., Geisen H.P., Fleischer K., Beersma M.F., Hoerauf A. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect. 2002, 4:43-50.
28. Sevilla N., Kunz S., Holz A., Lewicki H., Homann D., Yamada H., Campbell K.P., de La Torre J.C., Oldstone M.B. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 2000, 192:1249-1260.
29. Sevilla N., McGavern D.B., Teng C., Kunz S., Oldstone M.B. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J. Clin. Invest. 2004, 113:737-745.
30. Smelt S.C., Borrow P., Kunz S., Cao W., Tishon A., Lewicki H., Campbell K.P., Oldstone M.B. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. J. Virol. 2001, 75:448-457.
31. Spiropoulou C.F., Kunz S., Rollin P.E., Campbell K.P., Oldstone M.B. New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor. J. Virol. 2002, 76:5140-5146.
32. Sullivan B.M., Emonet S.F., Welch M.J., Lee A.M., Campbell K.P., de la Torre J.C., Oldstone M.B. Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. Proc. Natl. Acad. Sci. U.S.A 2011, 108:2969-2974.
33. Tishon A., Eddleston M., de la Torre J.C., Oldstone M.B. Cytotoxic T lymphocytes cleanse viral gene products from individually infected neurons and lymphocytes in mice persistently infected with lymphocytic choriomeningitis virus. Virology 1993, 197:463-467.
34. Urata S., Yun N., Pasquato A., Paessler S., Kunz S., de la Torre J.C. Antiviral activity of a small molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 2010.
35. Walsh K.B., Teijaro J.R., Zuniga E.I., Welch M.J., Fremgen D.M., Blackburn S.D., von Tiehl K.F., Wherry E.J., Flavell R.A., Oldstone M.B. Toll-like receptor 7 is required for effective adaptive immune responses that prevent persistent virus infection. Cell Host Microbe 2012, 11:643-653.
36. Welch M.J., Teijaro J.R., Lewicki H.A., Colonna M., Oldstone M.B. CD8 T cell defect of TNF-alpha and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection. Virology 2012, 429:163-170.
37. Wherry E.J. T-cell exhaustion. Nat. Immunol. 2011, 12:492-499.
38. Whitton J.L., Gebhard J.R., Lewicki H., Tishon A., Oldstone M.B. Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 1988, 62:687-695.
39. Whitton J.L., Southern P.J., Oldstone M.B. Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus. Virology 1988, 162:321-327.
40. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T-cells without effector function. J. Exp. Med. 1998, 188:2205-2213.